In recent years, a number of preclinical models have shown that cannabinoids may be highly effective at improving inflammation and, therefore, may be a potential treatment for inflammatory bowel diseases.
An opinion piece highlights the growing concerns among medical professionals about the exacerbating effects the COVID-19 pandemic may have among people with opioid use disorder.
In parallel to the ongoing national opioid crisis, the incidence rate of infective endocarditis cases has increased markedly among people aged 18 to 29 years with hepatitis C virus infection and those with opioid use disorder.
Compared with all opioid prescriptions, a higher hydromorphone controlled-release dispensing rate was a strong predictor of hepatitis C virus incidence.
![Still routinely prescribed to manage chronic pain, opioids are oftentimes overused, misused, or abused by patients. These behaviors are associated with a number of adverse effects, the most serious of which, respiratory depression, can result in death. Affectively dysregulated patients may associate negative emotions with recurrent opioid use through operant learning. [9] It is therefore imperative to prevent, identify, and manage opioid misuse in those patients, and seek to adopt of multi-dimensional approach to the treatment of chronic pain. Numerous initiatives have been initiated, aiming to guide healthcare practitioners in face of the opioid epidemic.](https://1tvlpc3ybbcb2e1tavrfrmg1-wpengine.netdna-ssl.com/wp-content/uploads/sites/15/2019/01/drugsspilledoutts509483224_1104058.jpg)
